article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.

article thumbnail

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Digital Health Global

The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the life sciences. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Where are HealthTech's soft landing M&A deals in today's market?

Lloyd Price

AI and machine learning: Companies with advanced AI solutions for tasks like drug discovery, clinical trial optimisation, and personalised medicine can be attractive targets. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.

article thumbnail

Accenture Invests in QuantHealth to Accelerate Use of AI-Powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

Healthcare IT Today

By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drug development. QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. Petra Jantzer, Ph.D., Originally announced January 8th, 2024

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88
article thumbnail

Uses of AI in Healthcare – 2024 Health IT Predictions

Healthcare IT Today

Precision medicine will continue to evolve in 2024: In disease areas like oncology, we will start to see AI playing a larger role in target discovery and biomarker or patient subpopulation identification, the cornerstones to early precision drug development.

Health IT 105